Efficacy and Safety of an Orally Administered DGAT2 Inhibitor Alone or Coadministered with a Liver-Targeted ACC Inhibitor in Adults with Non-Alcoholic Steatohepatitis (NASH): Rationale and Design of the Phase II, Dose-Ranging, Dose-Finding, Randomised, Placebo-Controlled MIRNA (metabolic Interventions to Resolve NASH with Fibrosis) Study
BMJ OPEN（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined